Hepato Cellular Carcinoma Clinical Trials

2 recruiting

Hepato Cellular Carcinoma Trials at a Glance

15 actively recruiting trials for hepato cellular carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Shanghai, Tanta, and Basel. Lead sponsors running hepato cellular carcinoma studies include Fudan University, Tanta University, and Haitao Zhao, MD.

Browse hepato cellular carcinoma trials by phase

Treatments under study

About Hepato Cellular Carcinoma Clinical Trials

Looking for clinical trials for Hepato Cellular Carcinoma? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepato Cellular Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepato Cellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

Hepato Cellular Carcinoma (HCC)Hand Foot Skin Syndrome
National Taiwan University Hospital39 enrolled1 locationNCT07560566
Recruiting
Not Applicable

PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)

CirrhosisHepato Cellular Carcinoma
Hospices Civils de Lyon100 enrolled1 locationNCT07393074
Recruiting
Phase 2

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Fudan University350 enrolled1 locationNCT07328009
Recruiting
Phase 2

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Fudan University40 enrolled1 locationNCT07536789
Recruiting
Phase 2

IIT2025-03-YANG-LIFT-HCC

Hepato Cellular Carcinoma
Ju Dong Yang41 enrolled1 locationNCT07489976
Recruiting
Not Applicable

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Intrahepatic CholangiocarcinomaHepato Cellular Carcinoma (HCC)
University Hospital, Angers206 enrolled14 locationsNCT06990659
Recruiting
Phase 2Phase 3

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
University Hospital, Basel, Switzerland152 enrolled3 locationsNCT07302919
Recruiting
Phase 2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Hepato Cellular Carcinoma (HCC)
IRCCS Azienda Ospedaliero-Universitaria di Bologna15 enrolled1 locationNCT07276100
Recruiting
Phase 3

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Chemotherapy EffectHepato Cellular Carcinoma (HCC)
Linhui Peng326 enrolled1 locationNCT07267806
Recruiting

Hepatocellular Carcinoma Identification Using Delta-HLD

Hepato Cellular Carcinoma (HCC)
Epiliquid Holding, Inc200 enrolled1 locationNCT07148310
Recruiting

Effect and Mechanism of ALPPS Operation on Liver Regeneration

Liver CancerHepatobiliary CancersLiver Regeneration+1 more
Haitao Zhao, MD50 enrolled1 locationNCT07142213
Recruiting

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)Portal Vein Tumour Thrombosis
Tanta University116 enrolled1 locationNCT06960954
Recruiting

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Tanta University80 enrolled1 locationNCT06960863
Recruiting
Phase 2

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Hepato Cellular Carcinoma (HCC)
Fudan University165 enrolled3 locationsNCT06812039
Recruiting
Phase 2

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Hepato Cellular Carcinoma (HCC)
West China Hospital36 enrolled1 locationNCT06742424